Zhao W, Dai Y, Yue L, Gu J, Meng E, Wang D, Liu S, Han X, Wang X, Li G, Dai X. Identification of a novel heterozygous germline RAD52 missense mutation in a patient with gallbladder carcinoma: A case report.
Medicine (Baltimore) 2021;
100:e25957. [PMID:
34106670 PMCID:
PMC8133115 DOI:
10.1097/md.0000000000025957]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Accepted: 04/28/2021] [Indexed: 11/26/2022] Open
Abstract
RATIONALE
Gallbladder carcinoma is a malignant biliary tract tumor which is characterized by poor prognosis. Recent advances in genomic medicine have identified a few novel germline mutations that contribute to the increased risk of gallbladder carcinoma. RAD52 is a crucial human deoxyribonucleic acid (DNA) repair gene involved in maintaining genomic stability and preventing tumor occurrence.
PATIENT CONCERNS
A 57-year-old man was hospitalized for space-occupying lesions in the gallbladder.
DIAGNOSIS
A diagnosis of gallbladder adenocarcinoma was made based on computed tomography, B-ultrasound, blood tests, and postoperative pathology.
INTERVENTIONS
Next-generation sequencing using a 599-gene panel and Sanger sequencing were performed to validate the mutation in the proband and his family members, respectively.
OUTCOMES
A novel potentially pathogenic heterozygous germline RAD52 missense mutation (c.276T > A: p.N92K) was identified in the patient. Sanger sequencing revealed that this variation was not observed in unaffected family members.
LESSONS
We identified a novel heterozygous germline RAD52 missense mutation in a patient with gallbladder carcinoma. Our results added to the current body of knowledge. It also provides new insights into genetic counseling and targeted therapeutic strategies for patients with gallbladder carcinoma.
Collapse